Additional file 1 of Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma

Additional file 1: Table S1. Clinical annotations of 128 GBM samples used in the study. Table S2. Variants identified by WES and GliomaSCAN. Table S3. Copy number alteration by WES and/or RNA-seq. Table S4. EGFRvIII detection in RNA-seq available samples. Table S5. Input file used for machine learning training.

补充材料1：
表S1：本研究中使用的128例胶质母细胞瘤（Glioblastoma Multiforme，GBM）样本的临床注释信息。
表S2：经全外显子测序（Whole Exome Sequencing，WES）与GliomaSCAN鉴定得到的基因组变异位点详情。
表S3：经WES和/或RNA测序（RNA-sequencing，RNA-seq）检测得到的拷贝数变异情况。
表S4：可获取RNA-seq数据的样本中表皮生长因子受体变异III（Epidermal Growth Factor Receptor Variant III，EGFRvIII）的检测结果。
表S5：机器学习训练所用的输入文件。